Clinical Characteristics of Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction
- 1 May 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Heart Failure
- Vol. 4 (3), 257-265
- https://doi.org/10.1161/circheartfailure.110.958801
Abstract
Background—: Pulmonary vascular disease associated with left-side heart failure and preserved ejection fraction (PH-HFpEF) is an increasingly common cause of pulmonary hypertension. The distinction between PH-HFpEF and pulmonary arterial hypertension (PAH) is important because therapies indicated for PAH can be detrimental in HFpEF. The characteristic features of PH-HFpEF are understudied. Methods and Results—: In a cross-sectional study, we compared the clinical, echocardiographic, and hemodynamic features of PH-HFpEF (n=100), with PAH (n=522), and HFpEF without pulmonary vascular disease (n=45). We determined the clinical characteristics that best differentiated PH-HFpEF from PAH. Compared with patients with PAH, patients with PH-HFpEF were older; had a higher prevalence of cardiovascular comorbidities; had worse exercise capacity and renal function; more frequently had left atrial enlargement; and less frequently had right atrial enlargement. PH was less severe in PH-HFpEF patients than in PAH patients (pulmonary vascular resistance 4.8 [interquartile range 3 to 8.4] versus 10.9 [interquartile range 7.4 to 15.7] Wood units; P <0.001). Old age, the presence of hypertension and coronary artery disease, the absence of right atrial enlargement, higher aortic systolic pressure, higher mean right atrial pressure, and higher cardiac output best differentiated PH-HFpEF from PAH (area under the receiver operating characteristics curve; curve 0.97). Compared with HFpEF patients without pulmonary hypertension, PH-HFpEF patients were often female and more symptomatic, more often had right ventricular hypertrophy and right atrial enlargement, and had higher right atrial pressure. Conclusions—: These data should help better identify PH-HFpEF, an entity that has become increasingly recognized and difficult to treat.Keywords
This publication has 34 references indexed in Scilit:
- Updated Clinical Classification of Pulmonary HypertensionJournal of the American College of Cardiology, 2009
- ACCF/AHA 2009 Expert Consensus Document on Pulmonary HypertensionJournal of the American College of Cardiology, 2009
- Heart Disease and Stroke Statistics—2009 UpdateCirculation, 2009
- Unexplained Pulmonary Hypertension in Elderly PatientsSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2007
- Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failureEuropean Journal of Heart Failure, 2005
- Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failureJournal of the American College of Cardiology, 2001
- A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST)American Heart Journal, 1997
- Diastolic left ventricular dysfunction leading to severe reversible pulmonary hypertensionAmerican Heart Journal, 1993
- Severe Pulmonary Hypertension Associated With Diastolic Left Ventricular DysfunctionSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1993
- Effects of Mitral-Valve Replacement on the Pulmonary Vascular Dynamics of Patients with Pulmonary HypertensionThe New England Journal of Medicine, 1965